Thursday, November 12, 2026

Nano Dimension Stock Went Down By Over 13% At Session Start Today

Nano Dimension Stock Went Down By Over 13% At Session Start Today

(VIANEWS) - Shares of Nano Dimension (NASDAQ: NNDM) dropped by a staggering 13.22% to $2.69 at 10:16 EST on Friday, following the last session's upward trend. NASDAQ is falling 2.05% to $11,338.35, following the last session's downward trend. This seems, at the moment, an all-around down trend exchanging session today.

Nano Dimension's last close was $3.10, 22.11% below its 52-week high of $3.98.

About Nano Dimension

Nano Dimension Ltd., together with its subsidiaries, provides additive electronics in Israel and internationally. The company's flagship product is DragonFly IV system that serves cross-industry High-Performance-Electronic-Devices' fabrication needs by depositing proprietary conductive and dielectric substances, as well as integrates in-situ capacitors, antennas, coils, transformers, and electromechanical components. It also provides nanotechnology based conductive and dielectric inks; and FLIGHT software platform that enables the 3D design of electrical and mechanical features. The company markets and sells products and services to companies that develop products with electronic components, including companies in the defense, automotive, consumer electronics, semiconductor, aerospace, and medical industries, as well as research institutes. Nano Dimension Ltd. was founded in 2012 and is headquartered in Ness Ziona, Israel.

Earnings Per Share

As for profitability, Nano Dimension has a trailing twelve months EPS of $-1.129.

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is negative -22.01%.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, Nano Dimension's stock is considered to be oversold (<=20).

More news about Nano Dimension (NNDM).

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Biotech Catalyst Wave: Late-2026 Clinical Readouts, PDUFA Dates and Capital Restructuring
A dense cluster of Q4 2026 to Q1 2027 clinical and regulatory catalysts spans hepatitis delta (Vir's ECLIPSE/SOLSTICE), hypertension and sleep apnea (Mineralys' lorundrostat, PDUFA 2026-12-22), severe hypertriglyceridemia (plozasiran), oncology (ivonescimab BLA, PDUFA 2026-11-14) and gene therapy (Krystal). Positive data flow from AASLD and AHA presentations is offset by cost-cutting guidance, milestones slipping into 2027, and a delisting process that signals capital-market stress for some issuers. Near-term value hinges on binary FDA decisions and Phase 3 topline readouts in Q1 2027.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,565 source documents archived
Query this data → isubstrate.com